Literature DB >> 22869890

Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample.

Jennifer J Griggs1, Sarah T Hawley, John J Graff, Ann S Hamilton, Reshma Jagsi, Nancy K Janz, Mahasin S Mujahid, Christopher R Friese, Barbara Salem, Paul H Abrahamse, Steven J Katz.   

Abstract

PURPOSE: Disparities in receipt of adjuvant chemotherapy may contribute to higher breast cancer fatality rates among black and Hispanic women compared with non-Hispanic whites. We investigated factors associated with receipt of chemotherapy in a diverse population-based sample. PATIENTS AND METHODS: Women diagnosed with breast cancer between August 2005 and May 2007 (N = 3,252) and reported to the Detroit, Michigan, or Los Angeles County Surveillance, Epidemiology, and End Results (SEER) registry were recruited to complete a survey. Multivariable analyses examined factors associated with chemotherapy receipt.
RESULTS: The survey was sent to 3,133 patients; 2,290 completed a survey (73.1%), and 1,403 of these patients were included in the analytic sample. In multivariable models, disease characteristics were significantly associated with the likelihood of receiving chemotherapy. Low-acculturated Hispanics were more likely to receive chemotherapy than non-Hispanic whites (odds ratio [OR], 2.00; 95% CI, 1.31 to 3.04), as were high-acculturated Hispanics (OR, 1.43; 95% CI, 1.03 to 1.98). Black women were less likely to receive chemotherapy than non-Hispanic whites, but the difference was not significant (OR, 0.83; 95% CI, 0.64 to 1.08). Increasing age (even in women age < 50 years) and Medicaid insurance were associated with lower rates of chemotherapy receipt.
CONCLUSION: In this population-based sample, disease characteristics were strongly associated with receipt of chemotherapy, indicating that clinical benefit guides most treatment decisions. We found no compelling evidence that black women and Hispanics receive chemotherapy at lower rates. Interventions that address chemotherapy use rates according to age and insurance status may improve quality of systemic treatment.

Entities:  

Mesh:

Year:  2012        PMID: 22869890      PMCID: PMC3732005          DOI: 10.1200/JCO.2012.41.9564

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  74 in total

1.  Disparities in health care by race, ethnicity, and language among the insured: findings from a national sample.

Authors:  Kevin Fiscella; Peter Franks; Mark P Doescher; Barry G Saver
Journal:  Med Care       Date:  2002-01       Impact factor: 2.983

2.  Socioeconomic status and breast carcinoma survival in four racial/ethnic groups: a population-based study.

Authors:  Cynthia D O'Malley; Gem M Le; Sally L Glaser; Sarah J Shema; Dee W West
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

3.  Older women with breast cancer: slow progress, great opportunity, now is the time.

Authors:  Hyman B Muss; Jan Busby-Whitehead
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

Review 4.  Defining and measuring acculturation: a systematic review of public health studies with Hispanic populations in the United States.

Authors:  Maria D Thomson; Laurie Hoffman-Goetz
Journal:  Soc Sci Med       Date:  2009-06-13       Impact factor: 4.634

5.  Insurance status and the use of guideline therapy in the treatment of selected cancers.

Authors:  Linda C Harlan; Amanda L Greene; Limin X Clegg; Margaret Mooney; Jennifer L Stevens; Martin L Brown
Journal:  J Clin Oncol       Date:  2005-11-21       Impact factor: 44.544

6.  Racial differences in breast carcinoma survival.

Authors:  S A Joslyn; M M West
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

7.  Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.

Authors:  Jennifer J Griggs; Eva Culakova; Melony E S Sorbero; Marek S Poniewierski; Debra A Wolff; Jeffrey Crawford; David C Dale; Gary H Lyman
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

8.  Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer.

Authors:  Michael J Hassett; Melissa E Hughes; Joyce C Niland; Stephen B Edge; Richard L Theriault; Yu-Ning Wong; John Wilson; W Bradford Carter; Douglas W Blayney; Jane C Weeks
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

9.  Latina patient perspectives about informed treatment decision making for breast cancer.

Authors:  Sarah T Hawley; Nancy K Janz; Ann Hamilton; Jennifer J Griggs; Amy K Alderman; Mahasin Mujahid; Steven J Katz
Journal:  Patient Educ Couns       Date:  2008-11

10.  Missed opportunities: racial disparities in adjuvant breast cancer treatment.

Authors:  Nina A Bickell; Jason J Wang; Soji Oluwole; Deborah Schrag; Henry Godfrey; Karen Hiotis; Jane Mendez; Amber A Guth
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

View more
  26 in total

1.  American Society of Clinical Oncology policy statement on medicaid reform.

Authors:  Blase N Polite; Jennifer J Griggs; Beverly Moy; Christopher Lathan; Nefertiti C duPont; Gina Villani; Sandra L Wong; Michael T Halpern
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

2.  Cross-Canada differences in early-stage breast cancer treatment and acute-care use.

Authors:  M Powis; P Groome; N Biswanger; C Kendell; K M Decker; E Grunfeld; M L McBride; R Urquhart; M Winget; G A Porter; M K Krzyzanowska
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

Review 3.  Present status of adjuvant chemotherapy for elderly breast cancer patients.

Authors:  Sibylle Loibl; Mattea Reinisch
Journal:  Breast Care (Basel)       Date:  2012-12       Impact factor: 2.860

4.  Racial/Ethnic and Socioeconomic Differences in Colorectal and Breast Cancer Treatment Quality: The Role of Physician-level Variations in Care.

Authors:  Ioana Popescu; Deborah Schrag; Alfonso Ang; Mitchell Wong
Journal:  Med Care       Date:  2016-08       Impact factor: 2.983

5.  Racial/ethnic differences in the utilization of chemotherapy among stage I-III breast cancer patients, stratified by subtype: Findings from ten National Program of Cancer Registries states.

Authors:  Lu Zhang; Jessica King; Xiao-Cheng Wu; Mei-Chin Hsieh; Vivien W Chen; Qingzhao Yu; Elizabeth Fontham; Michelle Loch; Lori A Pollack; Tekeda Ferguson
Journal:  Cancer Epidemiol       Date:  2018-11-08       Impact factor: 2.984

6.  Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer.

Authors:  Christopher R Friese; T May Pini; Yun Li; Paul H Abrahamse; John J Graff; Ann S Hamilton; Reshma Jagsi; Nancy K Janz; Sarah T Hawley; Steven J Katz; Jennifer J Griggs
Journal:  Breast Cancer Res Treat       Date:  2013-03-31       Impact factor: 4.872

7.  Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.

Authors:  Jennifer J Griggs; Ann S Hamilton; Kendra L Schwartz; Weiqiang Zhao; Paul H Abrahamse; Dafydd G Thomas; Julie M Jorns; Rachel Jewell; Maria E Sibug Saber; Reina Haque; Steven J Katz
Journal:  Breast Cancer Res Treat       Date:  2016-11-29       Impact factor: 4.872

8.  Providers of follow-up care in a population-based sample of breast cancer survivors.

Authors:  Christopher R Friese; Kathryn A Martinez; Paul Abrahamse; Ann S Hamilton; John J Graff; Reshma Jagsi; Jennifer J Griggs; Sarah T Hawley; Steven J Katz
Journal:  Breast Cancer Res Treat       Date:  2014-01-31       Impact factor: 4.872

9.  Decision Regret following Treatment for Localized Breast Cancer: Is Regret Stable Over Time?

Authors:  Kathryn A Martinez; Yun Li; Ken Resnicow; John J Graff; Ann S Hamilton; Sarah T Hawley
Journal:  Med Decis Making       Date:  2014-12-22       Impact factor: 2.583

10.  Underutilization of gene expression profiling for early-stage breast cancer in California.

Authors:  Rosemary D Cress; Yingjia S Chen; Cyllene R Morris; Helen Chew; Kenneth W Kizer
Journal:  Cancer Causes Control       Date:  2016-04-20       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.